Physician profile
David P Cornutt
NPI 1508928813
$42,374.81
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $2,692 · 2021: $9,770 · 2022: $3,086 · 2023: $42.46 · 2024: $32.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $74.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $74.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $14,899.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11,923.01 | 2021-2023 | Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,852.25 | 2019 | |
| Portola Pharmaceuticals, LLC | $2,674.88 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $932.11 | 2022-2024 | Andexxa |
| Pfizer INC. | $37.20 | 2021-2023 | |
| Vapotherm INC | $25.43 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.56 | 2020 | |
| Abbvie INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cornutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.